Company intelligence / Profile preview

ProArc Medical

Tel Aviv, Tel Aviv District, Israelproarcmedical.com ↗

Ownership: Private
Development stage: Commercial

Overview

ProArc Medical has developed the Omega system, a minimally invasive, implant-based solution for treating lower urinary tract symptoms caused by benign prostatic hyperplasia. The Omega system is currently being evaluated in multiple clinical trials, with early results indicating safety and efficacy in relieving urinary obstruction while preserving sexual function and minimizing complications

Therapeutic areas: Men's Health
Modalities: DeviceImplantable medical device (prostatic reshaping implant)
Industry: Implantable Medical Devices

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on ProArc Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProArc Medical.

Explore the full profile